Imagyn Laparoscopic Line Divestiture Lets Firm Focus On Oncology Devices
This article was originally published in The Gray Sheet
Executive Summary
Imagyn will use the nearly $30 mil. in proceeds from the sale of its minimal access surgery (MAS) products to Conmed to help launch three new oncology and critical care products.